BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38564826)

  • 1. Targeting EGFR degradation by autophagosome degraders.
    Zhu Z; Li J; Shen S; Al-Furas H; Li S; Tong Y; Li Y; Zeng Y; Feng Q; Chen K; Ma N; Zhou F; Zhang Z; Li Z; Pang J; Ding K; Xu F
    Eur J Med Chem; 2024 Apr; 270():116345. PubMed ID: 38564826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
    Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
    J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
    Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
    Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
    Ménard L; Floc'h N; Martin MJ; Cross DAE
    Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
    Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
    Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
    Yu T; Xia Q; Gong T; Wang J; Zhong D
    Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
    Kook E; Lee J; Kim DH
    Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors.
    Qian Y; Zhou S; Li J; Ma M; Chen H; Cao Y; Zhang Y; Sun C; Li K; Liu Y; Dai S; Ao M; Fang M; Wu Z; Li M
    Eur J Pharmacol; 2023 Dec; 960():176114. PubMed ID: 37863412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Kim M; Kim S; Yim J; Keam B; Kim TM; Jeon YK; Kim DW; Heo DS
    Cancer Res Treat; 2023 Oct; 55(4):1134-1143. PubMed ID: 37218137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
    Ma C; Zhang X; Mo X; Yu Y; Xiao Z; Wu J; Ding L; Lei C; Zhu Y; Zhang H
    Phytomedicine; 2024 Mar; 125():155351. PubMed ID: 38232540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.